Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. (Q53119214)

11 May 2018

http://europepmc.org/abstract/MED/28791873

title

Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. (English)

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

1 reference

Anagha Nadkarni

1

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

Donna McMorrow

series ordinal

2

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

Robert Fowler

series ordinal

3

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

David Smith

series ordinal

4

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

publication date

9 August 2017

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

published in

Journal of Comparative Effectiveness Research

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

volume

6

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

issue

8

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

page(s)

659-669

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

cites work

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Ten years with biologics: to whom do data on effectiveness and safety apply?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FCER-2017-0010

21 January 2018

Identifiers

DOI

10.2217/CER-2017-0010

1 reference

11 May 2018

http://europepmc.org/abstract/MED/28791873

1 reference

11 May 2018